| Revenue growth | 29% YoY growth in Q1 FY27. |
|---|---|
| Margins | Gross margins expanded 330 bps YoY to 62.7%. |
| Order book | Over 125 active projects in CDMO pipeline. |
| Demand visibility | Healthy order book in Affordable Medicines and CDMO pipeline. |
| Management confidence | High, citing strong CDMO momentum and manufacturing expansion. |
Growth
Revenue grew 29% YoY to ₹2,026 Cr; Net Profit surged 126% YoY to ₹368 Cr. CDMO small molecules revenue increased 69% YoY.
Outlook
Cumulative FY22-27 CAPEX target set at ₹4,700+ Cr. Fermentation facility (Vizag) commissioning expected by 3QFY27; ADC facility qualification by end 2027.
Risks
Global supply chain challenges persist. Bio segment revenue saw a 46% QoQ decline despite YoY growth.
Last quarter's promises, checked
Delivered
- Guided FY26 EBITDA margins 26.8% → delivered 26.8% (= BEAT)
- Guided FY26 Revenue ~₹6,800 Cr → delivered ₹6,813 Cr (= BEAT)
- Guided ARV Revenue quantum constant ~₹2,800 Cr → delivered ₹2,800 Cr (= BEAT)
Partly delivered
- Guided FY27 CDMO growth → delivered 67% YoY in Q1 (Partial: momentum high but FY target in progress)
Investor Presentation filed with BSE, NSE: LAURUSLABS. Summary written with AI assistance from the document.
Laurus Labs Ltd: key numbers
- Share price
- ₹2,052.80
- Market cap
- ₹1,10,915 Cr
- Revenue (annual)
- ₹6,813 Cr
- Net profit (annual)
- ₹888.8 Cr
- P/E (TTM)
- 101.4×Sector 47.4×
- Promoter holding
- 27.47%-0.02% QoQ
- FII holding
- 28.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Laurus Labs Ltd
All →Laurus Labs Investor Presentation: Key Takeaways
Laurus Labs delivered record Q1FY27 revenue of ₹2,026 Cr, a 29% YoY increase, driven by robust CDMO growth. EBITDA margins expanded 700 bps YoY to 31.8% on favorable mix.
Laurus Labs Other Announcement
Laurus Labs has been assigned an ESG score of 63 out of 100 for FY 2026 by NSE Sustainability Ratings and Analytics Limited.
Laurus Labs Employee Stock Options
Laurus Labs has allotted 62,635 equity shares to employees upon the exercise of vested stock options under its ESOP schemes.
Laurus Labs Merger & Restructuring
Laurus Labs announced the NCLT has issued an order regarding its Composite Scheme of Arrangement. The court directed notices be served for the upcoming September hearing.
Laurus Labs Earnings Call Transcript: Key Takeaways
Laurus Labs delivered record quarterly revenue and EBITDA margins, driven by strong CDMO commercial supplies and recovery in the affordable medicine portfolio.
- Call
- Guides 50% growth
Laurus Labs Results Update
Laurus Labs reported Q1 FY27 revenue of ₹2,026 Crore and EBITDA of ₹644 Crore. The results show 29% year-on-year revenue growth.